Form 4: Artiva Officer's Equity Grant and Tax Withholding
Insider Transaction Report
Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, reported an acquisition of 117,300 restricted stock units and a disposition of 2,187 shares for tax purposes.
Summary
- Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc. (ARTV), reported changes in his beneficial ownership.
- On February 15, 2026, Horan acquired 117,300 shares of Common Stock as a restricted stock unit (RSU) award under the Issuer's 2024 Equity Incentive Plan.
- The acquisition price for these RSUs was $0.
- Following this acquisition, Horan's beneficial ownership stood at 302,639 shares of Common Stock.
- Also on February 15, 2026, Horan disposed of 2,187 shares of Common Stock at a price of $4 per share.
- This disposition was due to shares being withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- After both transactions, Horan's beneficial ownership of Common Stock is 300,452 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing routine insider compensation and tax-related transactions rather than a significant change in company fundamentals or strategic direction.
Positives
- Christopher Horan received a grant of 117,300 restricted stock units, indicating continued equity-based compensation and alignment with shareholder interests.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that restricted stock unit grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with long-term company performance. The subsequent withholding of shares for tax purposes is a standard practice upon RSU vesting.
Stakeholder Impact
- Shareholders: The RSU grant aligns the Chief Tech Operations Officer's interests with long-term shareholder value. The tax-related disposition is a routine event and has minimal impact.
Key Dates
| Date | Description |
|---|---|
| 02/15/2026 | Transaction date for both the acquisition of restricted stock units and the disposition of shares for tax obligations. |
| 02/18/2026 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed. |
Keywords
Artiva Biotherapeutics, ARTV, Form 4, Insider Transaction, Restricted Stock Units, Equity Incentive Plan, Officer Compensation, Stock Award, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.